Create Free Account
By creating an account, you will get access to Hotstocks & curated emails.
or signup using
Already have a account? Login here.
ASX-listed clinical-stage biotech company Chimeric Therapeutics Limited (ASX:CHM) is engaged in developing ground-breaking CAR-T cell therapies for solid tumours. Chimeric Therapeutics’ CLTX-CAR-T technology incorporates a novel CAR-T recognition domain, chlorotoxin (CLTX), a peptide derived a scorpion’s venom. The Company is currently conducting Phase 1 clinical trials in glioblastoma (GBM) at the City of Hope Cancer Centre in Los Angeles, California.